OncoCyte Wins Buzz of BIO for the 2017 BIO CEO & Investor Conference
January 27 2017 - 7:00AM
OncoCyte Corporation (NYSE MKT:OCX), a developer of novel,
non-invasive tests for the early detection of
cancer, announced that the Biotechnology Innovation
Organization (BIO) has recognized OncoCyte Corporation as the Buzz
of BIO winner in the “diagnostics and beyond category” for the 2017
BIO CEO & Investor Conference taking place February 13–14 at
the Waldorf Astoria in New York. Nominated and selected by an
online vote, contest winners are recognized as innovative and
“buzzworthy” at the conference.
OncoCyte was selected because of its groundbreaking work in
cancer confirmatory diagnostics that can help physicians better
manage lung nodules to prevent avoidable procedures and reduce the
overall cost of lung cancer screening. “We believe that our
lung confirmatory test, which is currently in the development
stage, has the potential to reduce a significant number of risky
and avoidable biopsies,” commented William Annett, President &
Chief Executive Officer.
In addition to being honored with the award, OncoCyte will make
a company presentation as well as participate in partnering
sessions during the Conference.
“We are honored by our peers and
colleagues choosing us for the innovation award in our category and
believe that this is a reflection of the unmet need for tools to
help clinicians better manage patients with lung nodules,” said Dr.
Kristine C. Mechem, Vice President of Marketing. “If we are
successful with the final studies of our test, OncoCyte believes
that we can significantly improve the standard of care for lung
nodule management.”
About OncoCyte Corporation
OncoCyte is focused on the development and
commercialization of novel, non-invasive blood and urine (“liquid
biopsy”) diagnostic tests for the early detection of cancer to
improve health outcomes through earlier diagnoses, to reduce the
cost of care through the avoidance of more costly diagnostic
procedures, including invasive biopsy and cystoscopic procedures,
and to improve the quality of life for cancer patients.
While current biopsy tests use invasive surgical
procedures to provide tissue samples in order to determine if a
tumor is benign or malignant, OncoCyte is developing a next
generation of diagnostic tests that will be based on liquid
biopsies using blood or urine samples. OncoCyte’s pipeline products
are intended to be confirmatory diagnostics for lung, bladder and
breast cancer. OncoCyte’s diagnostic tests are being developed
using proprietary sets of genetic and protein biomarkers that are
differentially expressed in specific types of cancer. For more
information visit www.oncocyte.com.
ABOUT THE BIO CEO & INVESTOR
CONFERENCE
The 19th Annual BIO CEO & Investor Conference is one of the
largest investor conference focused on established and emerging
publicly traded and select private biotech companies. Because our
mission is to support industry-wide success, we present a broad and
unbiased view of investment opportunities. In addition, the
BIO CEO & Investor Conference draws business development
executives from leading global pharmaceutical and established
biotechnology companies.
Investor Contact:
EVC Group, Inc.
Michael Polyviou/Doug Sherk
646-445-4800
mpolyviou@evcgroup.com / dsherk@evcgroup.com